Who
Shlomo Yanai
Director
Company insider
Files Form 4 as: Director, Amneal Pharmaceuticals; Director, Philip Morris International; Director, W R Grace & Co; Director, Cambrex; Director, Pdl Biopharma; Director, Exela Technologies; Director, Sagent Pharmaceuticals; Director, Perrigo Company.
In numbers
- Trades disclosed
- 84
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $2.1M
- Companies
- 9
- Companies where not an officer
- 9
- First trade
- 28 Nov 2012
- Last trade
- 7 May 2026
- Last filed
- 8 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 May 2026filed 8 May 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —34,819 | filing |
| 7 May 2026filed 8 May 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —34,819 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —34,819 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —34,819 | filing |
| 6 May 2026filed 8 May 2026 | PM Philip Morris InternationalTobacco & Nicotine | SEC FORM 4 Code A | $190K1,119 at $169.93 | filing |
| 6 May 2026filed 8 May 2026 | PM Philip Morris InternationalTobacco & Nicotine | SEC FORM 4 Code A | $190K1,119 at $169.93 | filing |
| 6 May 2026filed 8 May 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —19,824 at $0.00 | filing |
| 6 May 2026filed 8 May 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —19,824 at $0.00 | filing |
| 7 May 2025filed 9 May 2025 | PM Philip Morris InternationalTobacco & Nicotine | SEC FORM 4 Code A | $175K1,002 at $174.82 | filing |
| 6 May 2025filed 8 May 2025 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —34,819 at $0.00 | filing |
| 5 May 2025filed 8 May 2025 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —40,258 at $0.00 | filing |
| 5 May 2025filed 8 May 2025 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —40,258 | filing |
| 10 May 2024filed 14 May 2024 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —76,453 at $0.00 | filing |
| 10 May 2024filed 14 May 2024 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —76,453 | filing |
| 8 May 2024filed 10 May 2024 | PM Philip Morris InternationalTobacco & Nicotine | SEC FORM 4 Code A | $175K1,789 at $97.84 | filing |
| 2 May 2024filed 6 May 2024 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —40,258 at $0.00 | filing |
| 10 May 2023filed 11 May 2023 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —80,128 at $0.00 | filing |
| 10 May 2023filed 11 May 2023 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —80,128 | filing |
| 9 May 2023filed 11 May 2023 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —76,453 at $0.00 | filing |
| 3 May 2023filed 5 May 2023 | PM Philip Morris InternationalTobacco & Nicotine | SEC FORM 4 Code A | $175K1,812 at $96.58 | filing |
News
No headline names them, or the companies they trade most, lately.